NCT07931313
PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer
At risk: Primary endpoint(s) modified, enrollment reduced 76%.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Enrollment reduced: 534 → 130 participants Show 5 more changesShow less
- Primary endpoint(s) modified
- Phase changed: Phase 2/3 → Phase 2
- Primary and study completion moved earlier from Feb 28, 2037 to Jun 30, 2029
- Secondary endpoints: 6 to 3
- Study description expanded, about 1 word
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (3)
Arms and interventions
Maximal-effort cytoreductive surgery will be completed within 3 weeks after pathologic diagnosis, followed by 6 cycles of first-line chemotherapy. The interval from surgery to the first postoperative chemotherapy cycle should not exceed 8 weeks unless medically necessary.
Participants will receive 3 cycles of neoadjuvant chemotherapy, undergo interval debulking surgery with maximal-effort cytoreduction, and then receive 3 additional cycles of chemotherapy. The interval from surgery to the first postoperative chemotherapy cycle should not exceed 8 weeks unless medically necessary.
Procedures: Upfront cytoreductive surgery, Interval debulking surgery
Drugs: Platinum-based chemotherapy
Sites
2 sites in 1 country